Clinical Trial Detail

NCT ID NCT02281409
Title Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Memorial Sloan Kettering Cancer Center
Indications

Advanced Solid Tumor

triple-receptor negative breast cancer

stomach cancer

lung non-small cell carcinoma

Therapies

Mogamulizumab

Age Groups: adult senior

Additional content available in CKB BOOST